Follow the AKTIS ONCOLOGY, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.5bn. The latest transaction was disclosed on 21 July 2026 (Levée d'options). Among the most active insiders: Herrmann Ken. Every trade is openly available.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€3m
9 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AKTIS ONCOLOGY, INC. Strong Buy (bullish), based on 8 analysts. Average price target: US$34.81.
41Σ signal
Buys n/a€3m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AKTIS ONCOLOGY, INC. es una empresa centrada en el desarrollo de tratamientos innovadores contra el cáncer. Se especializa en terapias dirigidas para mejorar los resultados de los pacientes.